Clinical evidence from extension trials suggests this reduces monthly costs by 2540% while maintaining 6075% of the weight loss achieved at higher doses, though individual response varies significantly
The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently
On top of that, one of the biggest complaints about GLP-1s, when taken according to the standard doses approved by the FDA is that they cause side effects such as nausea, diarrhea and fatigue
doi: 10.1038/228620a0 28 QianB-ZPollardJW